An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer
- Conditions
- advanced ovarian cancerMedDRA version: 17.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
- Registration Number
- EUCTR2014-002014-22-HU
- Lead Sponsor
- Országos Onkológiai Intézet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Histological proven ovarian cancer
Advanced cancer
ECOG 0-3
Appropriate laboratory functions
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
-
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Progression free survival;Secondary Objective: Overall survival;Primary end point(s): Progression of cancer ;Timepoint(s) of evaluation of this end point: -
- Secondary Outcome Measures
Name Time Method Secondary end point(s): Progression of cancer ;Timepoint(s) of evaluation of this end point: -